BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $AZN readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06219941-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261118
SUMMARY:AZD0901 readout (P2) · AstraZeneca $AZN
DESCRIPTION:AZD0901 in Participants With Advanced Solid Tumours Expressing 
 Claudin18.2\n\nPrimary completion date: 2026-11-17 (estimated)\nOriginally
  planned: 2025-03-25 (+19.8 months)\nPhase 2 · Oncology · Gastric Cancer
 \, Gastroesophageal Junction Cancer\, Biliary Tract Cancer\nEnrollment: 22
 6 · Sites: 52\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://tria
 lsonar.netlify.app/radar.html?nct=NCT06219941\nhttps://clinicaltrials.gov/
 study/NCT06219941
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06219941
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081633-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TREMENDOUS-2 readout (P2) · AstraZeneca $AZN
DESCRIPTION:Durvalumab and Tremelimumab With Lenvatinib as First-line Treat
 ment in Patients With Unresectable Hepatocellular Carcinoma\n\nPrimary com
 pletion date: 2026-11-30 (estimated)\nPhase 2 · Oncology · Hepatocellula
 r Carcinoma\nEnrollment: 114 · Sites: 23\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07081633\n
 https://clinicaltrials.gov/study/NCT07081633
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07081633
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724809-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:ECU-NMO-304 readout (P3) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Efficacy\, Safety\, PK\, PD\, and ADA of Eculizumab in Chinese 
 Adults With NMOSD\n\nPrimary completion date: 2026-12-07 (estimated)\nOrig
 inally planned: 2027-03-30 (-3.7 months)\nPhase 3 · Neuro · NMOSD\, Neur
 omyelitis Optica Spectrum Disorders\nEnrollment: 21 · Sites: 7\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.
 html?nct=NCT06724809\nhttps://clinicaltrials.gov/study/NCT06724809
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06724809
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:BaxDuo-Baltic readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Co
 mbination With Baxdrostat Compared With Baxdrostat on Albuminuria in Parti
 cipants With Chronic Kidney Disease and Hi…\n\nPrimary completion date: 
 2026-12-10 (estimated)\nOriginally planned: 2027-05-24 (-5.4 months)\nPhas
 e 2 · Cardio-Met · Chronic Kidney Disease and Hypertension\nEnrollment: 
 222 · Sites: 55\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tr
 ialsonar.netlify.app/radar.html?nct=NCT07222917\nhttps://clinicaltrials.go
 v/study/NCT07222917
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07222917
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607627-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Gefurulimab readout (P3) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatr
 ic Patients With AChR+ Generalized Myasthenia Gravis\n\nPrimary completion
  date: 2026-12-15 (estimated)\nOriginally planned: 2027-04-02 (-3.5 months
 )\nPhase 3 · Oncology · Generalized Myasthenia Gravis\, gMG\nEnrollment:
  12 · Sites: 13\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tr
 ialsonar.netlify.app/radar.html?nct=NCT06607627\nhttps://clinicaltrials.go
 v/study/NCT06607627
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06607627
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692180-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:DOMINICA readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Multicentre\, Randomised\, Double-blind\, Parallel Group\, Pl
 acebo-controlled\, Time-to-first Asthma Exacerbation Phase III Efficacy an
 d Safety Study of Benralizumab in Paediatric Pa…\n\nPrimary completion d
 ate: 2026-12-23 (estimated)\nOriginally planned: 2030-05-05 (-40.4 months)
 \nPhase 3 · Respiratory · Asthma\nEnrollment: 94 · Sites: 43\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.
 html?nct=NCT05692180\nhttps://clinicaltrials.gov/study/NCT05692180
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05692180
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303532-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ROSY-D readout (P3) · AstraZeneca $AZN
DESCRIPTION:Roll Over StudY for Patients Who Have Completed a Previous Onco
 logy Study With Durvalumab\n\nPrimary completion date: 2026-12-31 (estimat
 ed)\nOriginally planned: 2024-11-08 (+25.7 months)\nPhase 3 · Oncology ·
  Cancer\nEnrollment: 214 · Sites: 123\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05303532\nhtt
 ps://clinicaltrials.gov/study/NCT05303532
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05303532
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000136-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:AZURE-HeFH readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With HeFH\n\nPrimary completion date: 2027-01-04 (estimated)\nOrig
 inally planned: 2027-03-26 (-2.7 months)\nPhase 3 · Cardio-Met · Heteroz
 ygous Familial Hypercholesterolaemia\nEnrollment: 473 · Sites: 133\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/ra
 dar.html?nct=NCT07000136\nhttps://clinicaltrials.gov/study/NCT07000136
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07000136
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925803-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:DAISY readout (P3) · AstraZeneca $AZN
DESCRIPTION:Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (D
 AISY)\n\nPrimary completion date: 2027-01-06 (estimated)\nOriginally plann
 ed: 2027-12-31 (-11.8 months)\nPhase 3 · Immuno · Systemic Sclerosis\, S
 cleroderma\nEnrollment: 314 · Sites: 151\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05925803\n
 https://clinicaltrials.gov/study/NCT05925803
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05925803
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05221840-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:PACIFIC-9 readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Global Study to Assess the Effects of Durvalumab With Oleclum
 ab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in P
 atients With Stage III Unresectable Non-Sm…\n\nPrimary completion date: 
 2027-01-08 (estimated)\nOriginally planned: 2026-06-18 (+6.7 months)\nPhas
 e 3 · Oncology · Non-Small Cell Lung Cancer\nEnrollment: 1051 · Sites: 
 202\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netl
 ify.app/radar.html?nct=NCT05221840\nhttps://clinicaltrials.gov/study/NCT05
 221840
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05221840
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:TROPION-Lung15 readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Dato-DXd With
  or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy 
 in Participants With EGFR-Mutated Locally …\n\nPrimary completion date: 
 2027-01-11 (estimated)\nOriginally planned: 2026-09-08 (+4.1 months)\nPhas
 e 3 · Oncology · Metastatic Non-small Cell Lung Cancer\nEnrollment: 768 
 · Sites: 211\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT06417814\nhttps://clinicaltrials.gov/s
 tudy/NCT06417814
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06417814
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000123-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:AZURE-LDL readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With Clinical ASCVD or at Risk for a First ASCVD Event\n\nPrimary 
 completion date: 2027-01-11 (estimated)\nOriginally planned: 2027-03-26 (-
 2.4 months)\nPhase 3 · Cardio-Met · Cardiovascular Disease\nEnrollment: 
 3103 · Sites: 404\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 trialsonar.netlify.app/radar.html?nct=NCT07000123\nhttps://clinicaltrials.
 gov/study/NCT07000123
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07000123
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706817-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:ESSENCE readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate Changes in Symptoms in Adult Participant
 s With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment Wi
 th Tezepelumab\n\nPrimary completion date: 2027-01-13 (estimated)\nPhase 3
  · Infectious · Chronic Rhinosinusitis With Nasal Polyps\nEnrollment: 18
 1 · Sites: 41\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://tria
 lsonar.netlify.app/radar.html?nct=NCT06706817\nhttps://clinicaltrials.gov/
 study/NCT06706817
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06706817
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:SOUND readout (P2) · AstraZeneca $AZN
DESCRIPTION:Savolitinib Combine With Durvalumab in EGFR Wild-type Locally A
 dvanced or Metastatic NSCLC\n\nPrimary completion date: 2027-01-18 (estima
 ted)\nOriginally planned: 2023-10-31 (+38.6 months)\nPhase 2 · Oncology 
 · Lung Cancer\nEnrollment: 47 · Sites: 16\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05374603
 \nhttps://clinicaltrials.gov/study/NCT05374603
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05374603
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Trastuzumab deruxtecan readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study of T-DXd as Monotherapy or in Combination With Anti-can
 cer Agents in Patients With Selected HER2-expressing Tumors\n\nPrimary com
 pletion date: 2027-02-10 (estimated)\nOriginally planned: 2025-10-30 (+15.
 4 months)\nPhase 2 · Oncology · Advanced Solid Tumors (Excluding Gastric
  Cancer and Breast …\nEnrollment: 127 · Sites: 29\n\nPrimary completion
  = last participant's primary-endpoint data collected\; topline results us
 ually follow weeks to months later. Sponsor-reported\, often an estimate. 
 Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NC
 T06271837\nhttps://clinicaltrials.gov/study/NCT06271837
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06271837
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215702-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:SERENIA readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate the Efficacy\, Safety\, and Tolerability
  of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.\n\n
 Primary completion date: 2027-02-11 (estimated)\nPhase 2 · Infectious · 
 Sepsis\, Acute Kidney Injury\nEnrollment: 124 · Sites: 74\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?
 nct=NCT07215702\nhttps://clinicaltrials.gov/study/NCT07215702
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07215702
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087835-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Zibotentan/Dapagliflozin readout (P3) · AstraZeneca $AZN
DESCRIPTION:Study to Investigate Efficacy\, Safety\, and Tolerability of Zi
 botentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chro
 nic Kidney Disease and High Proteinuria (ZEN…\n\nPrimary completion date
 : 2027-02-18 (estimated)\nOriginally planned: 2027-07-05 (-4.5 months)\nPh
 ase 3 · Cardio-Met · Chronic Kidney Disease With High Proteinuria\nEnrol
 lment: 1835 · Sites: 296\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://trialsonar.netlify.app/radar.html?nct=NCT06087835\nhttps://clinical
 trials.gov/study/NCT06087835
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06087835
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629234-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:ROSY-T readout (P3) · AstraZeneca $AZN
DESCRIPTION:Roll Over StudY for Patients Who Have Completed a Previous Onco
 logy Study With Osimertinib (TAGRISSO) (ROSY-T)\n\nPrimary completion date
 : 2027-02-22 (estimated)\nOriginally planned: 2026-03-13 (+11.4 months)\nP
 hase 3 · Oncology · Cancer\nEnrollment: 37 · Sites: 27\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?n
 ct=NCT05629234\nhttps://clinicaltrials.gov/study/NCT05629234
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05629234
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834932-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Rosuvastatin Dose 1 readout (P2/3) · AstraZeneca $AZN
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetic
 s of AZD0780 in Participants With Dyslipidaemia\n\nPrimary completion date
 : 2027-02-22 (estimated)\nOriginally planned: 2025-06-26 (+19.9 months)\nP
 hase 2/3 · Cardio-Met · Dyslipidaemia\nEnrollment: 432 · Sites: 40\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/
 radar.html?nct=NCT06834932\nhttps://clinicaltrials.gov/study/NCT06834932
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06834932
CATEGORIES:Cardio-Met,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138133-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:IRIS readout (P3) · AstraZeneca $AZN
DESCRIPTION:Phase 3 Study of Anifrolumab in Adult Patients With Active Prol
 iferative Lupus Nephritis\n\nPrimary completion date: 2027-02-23 (estimate
 d)\nOriginally planned: 2025-10-30 (+15.8 months)\nPhase 3 · Immuno · Lu
 pus Nephritis\nEnrollment: 363 · Sites: 164\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0513813
 3\nhttps://clinicaltrials.gov/study/NCT05138133
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05138133
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04482309-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:DPT02 readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Phase 2 Study of T-DXd in Patients With Selected HER2 Express
 ing Tumors\n\nPrimary completion date: 2027-03-23 (estimated)\nOriginally 
 planned: 2023-03-24 (+48.0 months)\nPhase 2 · Oncology · Part 1: Bladder
 \, Biliary Tract\, Cervical\, Endometrial\, Ovar…\, Part 2: HER2 Express
 ing/Amplified Solid Tumors Excluding Br…\nEnrollment: 477 · Sites: 89\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT04482309\nhttps://clinicaltrials.gov/study/NCT0448230
 9
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04482309
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:ROSY-O readout (P3) · AstraZeneca $AZN
DESCRIPTION:Roll Over StudY for Patients Who Have Completed a Previous Onco
 logy Study With Olaparib\n\nPrimary completion date: 2027-04-06 (estimated
 )\nOriginally planned: 2025-03-24 (+24.4 months)\nPhase 3 · Oncology · O
 varian Cancer\, Breast Cancer\nEnrollment: 185 · Sites: 107\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT04421963\nhttps://clinicaltrials.gov/study/NCT04421963
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04421963
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:BalanceD-HF readout (P3) · AstraZeneca $AZN
DESCRIPTION:Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in P
 atients With Heart Failure and Impaired Kidney Function\n\nPrimary complet
 ion date: 2027-04-16 (estimated)\nOriginally planned: 2027-06-11 (-1.8 mon
 ths)\nPhase 3 · Cardio-Met · Heart Failure and Impaired Kidney Function\
 nEnrollment: 3850 · Sites: 852\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06307652\nhttps://cl
 inicaltrials.gov/study/NCT06307652
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06307652
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05774951-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:CAMBRIA-1 readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study of Camizestrant in ER+/HER2- Early Breast Cancer After 
 at Least 2 Years of Standard Adjuvant Endocrine Therapy\n\nPrimary complet
 ion date: 2027-04-20 (estimated)\nPhase 3 · Oncology · Breast Cancer\, E
 arly Breast Cancer\nEnrollment: 4300 · Sites: 709\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0
 5774951\nhttps://clinicaltrials.gov/study/NCT05774951
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05774951
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285213-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:PRISM readout (P2) · AstraZeneca $AZN
DESCRIPTION:Prevention of Recurrent C. Difficile Infection Study With AZD51
 48 Monoclonal Antibody\n\nPrimary completion date: 2027-04-20 (estimated)\
 nPhase 2 · Infectious · Clostridioides Difficile Infection\nEnrollment: 
 230 · Sites: 117\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://t
 rialsonar.netlify.app/radar.html?nct=NCT07285213\nhttps://clinicaltrials.g
 ov/study/NCT07285213
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07285213
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab deruxtecan readout (P3) · AstraZeneca $AZN
DESCRIPTION:Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versu
 s Taxane\, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast C
 ancer (DESTINY-Breast09)\n\nPrimary completion date: 2027-05-03 (estimated
 )\nOriginally planned: 2025-07-30 (+21.1 months)\nPhase 3 · Oncology · B
 reast Cancer\; HER2-positive\; Metastatic\nEnrollment: 1157 · Sites: 283\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT04784715\nhttps://clinicaltrials.gov/study/NCT047847
 15
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04784715
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:DG-03 readout (P2) · AstraZeneca $AZN
DESCRIPTION:Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations i
 n Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)\n\nPrimary c
 ompletion date: 2027-05-04 (estimated)\nOriginally planned: 2022-12-27 (+5
 2.2 months)\nPhase 2 · Oncology · Gastric Cancer\nEnrollment: 452 · Sit
 es: 71\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.n
 etlify.app/radar.html?nct=NCT04379596\nhttps://clinicaltrials.gov/study/NC
 T04379596
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04379596
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Danicopan readout (P3) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Study of Danicopan as Add-on Treatment to Ravulizumab or Eculiz
 umab in Pediatric Participants With PNH Who Have Clinically Significant Ex
 travascular Hemolysis\n\nPrimary completion date: 2027-05-28 (estimated)\n
 Originally planned: 2027-01-15 (+4.4 months)\nPhase 3 · GI·Renal·Heme 
 · Paroxysmal Nocturnal Hemoglobinuria\, PNH\, Extravascular Hemolysis\nEn
 rollment: 6 · Sites: 4\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://trialsonar.netlify.app/radar.html?nct=NCT06449001\nhttps://clinicaltr
 ials.gov/study/NCT06449001
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06449001
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:laroprovstat/rosuvastatin 1 readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosu
 vastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholest
 erolaemia\n\nPrimary completion date: 2027-05-28 (estimated)\nPhase 3 · C
 ardio-Met · Hypercholesterolaemia\nEnrollment: 200 · Sites: 45\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar
 .html?nct=NCT07619118\nhttps://clinicaltrials.gov/study/NCT07619118
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07619118
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932263-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:Umbriel readout (P2) · AstraZeneca $AZN
DESCRIPTION:Dose Range Finding Study to Assess Efficacy and Safety of Tozor
 akimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled C
 orticosteroids\n\nPrimary completion date: 2027-06-07 (estimated)\nOrigina
 lly planned: 2027-07-12 (-1.1 months)\nPhase 2 · Respiratory · Asthma\nE
 nrollment: 540 · Sites: 223\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://trialsonar.netlify.app/radar.html?nct=NCT06932263\nhttps://clini
 caltrials.gov/study/NCT06932263
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06932263
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:ARRIVAL readout (P3) · AstraZeneca $AZN
DESCRIPTION:Open-label Study to Assess Reduction of Background Asthma Medic
 ation While Sustaining Asthma Control and Clinical Remission With Tezepelu
 mab in Patients 12-80yrs With Severe Asthm…\n\nPrimary completion date: 
 2027-06-25 (estimated)\nPhase 3 · Respiratory · Severe Asthma\nEnrollmen
 t: 310 · Sites: 70\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /trialsonar.netlify.app/radar.html?nct=NCT06473779\nhttps://clinicaltrials
 .gov/study/NCT06473779
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06473779
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04550260-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:KUNLUN readout (P3) · AstraZeneca $AZN
DESCRIPTION:Study of Durvalumab Versus Placebo in Combination With Definiti
 ve Chemoradiation Therapy in Patient With ESCC\n\nPrimary completion date:
  2027-06-30 (estimated)\nOriginally planned: 2025-06-30 (+24.0 months)\nPh
 ase 3 · Oncology · Esophageal Squamous Cell Carcinoma\nEnrollment: 640 
 · Sites: 133\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT04550260\nhttps://clinicaltrials.gov/s
 tudy/NCT04550260
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04550260
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792695-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:CANTOR readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study of Novel Study Interventions and Combinations in Partic
 ipants With Colorectal Cancer\n\nPrimary completion date: 2027-06-30 (esti
 mated)\nOriginally planned: 2027-03-31 (+3.0 months)\nPhase 2 · Oncology 
 · Metastatic Colorectal Cancer\nEnrollment: 82 · Sites: 56\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT06792695\nhttps://clinicaltrials.gov/study/NCT06792695
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06792695
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157787-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:AUTUMN readout (P2) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Study of ALXN1920 in Adult Participants With Primary Membranous
  Nephropathy (PMN)\n\nPrimary completion date: 2027-07-02 (estimated)\nOri
 ginally planned: 2027-03-12 (+3.7 months)\nPhase 2 · GI·Renal·Heme · P
 rimary Membranous Nephropathy\nEnrollment: 30 · Sites: 40\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?
 nct=NCT07157787\nhttps://clinicaltrials.gov/study/NCT07157787
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07157787
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610837-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:BRAVO readout (P2) · AstraZeneca $AZN
DESCRIPTION:Study of AZD2389 Safety\, Tolerability\, and Pharmacodynamics i
 n Adults With Steatotic Liver Disease and Advanced Fibrosis\n\nPrimary com
 pletion date: 2027-07-07 (estimated)\nPhase 2 · GI·Renal·Heme · Liver 
 Fibrosis\, Hepatic Cirrhosis\nEnrollment: 104 · Sites: 22\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?
 nct=NCT07610837\nhttps://clinicaltrials.gov/study/NCT07610837
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07610837
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:MAJIC readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus
  Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Smal
 l Lymphocytic Lymphoma\n\nPrimary completion date: 2027-07-15 (estimated)\
 nOriginally planned: 2028-09-29 (-14.5 months)\nPhase 3 · Oncology · Chr
 onic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEnrollment: 607 
 · Sites: 37\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://trials
 onar.netlify.app/radar.html?nct=NCT05057494\nhttps://clinicaltrials.gov/st
 udy/NCT05057494
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05057494
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007793-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:BaxPA readout (P3) · AstraZeneca $AZN
DESCRIPTION:Parent Study: A Study to Assess Efficacy and Safety of Baxdrost
 at in Participants With Primary Aldosteronism Sub-study: A Follow-up Subst
 udy After Completion of the BaxPA Main Stu…\n\nPrimary completion date: 
 2027-07-27 (estimated)\nOriginally planned: 2028-02-18 (-6.8 months)\nPhas
 e 3 · Cardio-Met · Primary Hyperaldosteronism\nEnrollment: 212 · Sites:
  76\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netl
 ify.app/radar.html?nct=NCT07007793\nhttps://clinicaltrials.gov/study/NCT07
 007793
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07007793
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Dato-DXd readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study of Dato-DXd With or Without Durvalumab Compar
 ed With Investigator's Choice of Chemotherapy in Combination With Pembroli
 zumab in Patients With PD-L1 Positive Loca…\n\nPrimary completion date: 
 2027-07-28 (estimated)\nOriginally planned: 2026-09-14 (+10.4 months)\nPha
 se 3 · Oncology · Breast Cancer\nEnrollment: 625 · Sites: 318\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar
 .html?nct=NCT06103864\nhttps://clinicaltrials.gov/study/NCT06103864
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06103864
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:eVOLVE-01 readout (P2) · AstraZeneca $AZN
DESCRIPTION:Volrustomig Priming Regimens Exploratory Phase II Platform Stud
 y\n\nPrimary completion date: 2027-07-30 (estimated)\nOriginally planned: 
 2025-08-26 (+23.1 months)\nPhase 2 · Oncology · Non-small Cell Lung Canc
 er\nEnrollment: 194 · Sites: 63\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06448754\nhttps://c
 linicaltrials.gov/study/NCT06448754
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06448754
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Laroprovstat readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosu
 vastatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in
  LLT-naïve Patients.\n\nPrimary completion date: 2027-07-30 (estimated)\n
 Phase 3 · Cardio-Met · Hypercholesterolaemia\nEnrollment: 600 · Sites: 
 152\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netl
 ify.app/radar.html?nct=NCT07619131\nhttps://clinicaltrials.gov/study/NCT07
 619131
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07619131
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120349-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:ADAURA2 readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Global Study to Assess the Effects of Osimertinib in Particip
 ants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection\n\
 nPrimary completion date: 2027-08-02 (estimated)\nPhase 3 · Oncology · N
 on-Small Cell Lung Cancer\nEnrollment: 390 · Sites: 139\n\nPrimary comple
 tion = last participant's primary-endpoint data collected\; topline result
 s usually follow weeks to months later. Sponsor-reported\, often an estima
 te. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nc
 t=NCT05120349\nhttps://clinicaltrials.gov/study/NCT05120349
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05120349
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596784-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ravulizumab readout (P3) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Efficacy and Safety of Ravulizumab in Chinese Adults Participan
 ts With Generalized Myasthenia Gravis (gMG)\n\nPrimary completion date: 20
 27-08-24 (estimated)\nPhase 3 · Oncology · Generalized Myasthenia Gravis
 \, gMG\nEnrollment: 20 · Sites: 10\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07596784\nhttps:
 //clinicaltrials.gov/study/NCT07596784
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07596784
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082738-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:PRESTO readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate the Effect of AZD6793 in Participants Wi
 th Moderate to Very Severe Chronic Obstructive Pulmonary Disease\n\nPrimar
 y completion date: 2027-08-31 (estimated)\nOriginally planned: 2027-11-05 
 (-2.2 months)\nPhase 2 · Respiratory · Chronic Obstructive Pulmonary Dis
 ease (COPD)\nEnrollment: 987 · Sites: 367\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07082738\
 nhttps://clinicaltrials.gov/study/NCT07082738
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07082738
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dato-DXd readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study of Dato-DXd With or Without Durvalumab Versus Investiga
 tor's Choice of Therapy in Patients With Stage I-III Triple-negative Breas
 t Cancer Without Pathological Complete Res…\n\nPrimary completion date: 
 2027-09-01 (estimated)\nPhase 3 · Oncology · Breast Cancer\nEnrollment: 
 1174 · Sites: 276\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 trialsonar.netlify.app/radar.html?nct=NCT05629585\nhttps://clinicaltrials.
 gov/study/NCT05629585
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05629585
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120491-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:EvoPAR-PR01 readout (P3) · AstraZeneca $AZN
DESCRIPTION:Saruparib (AZD5305) vs Placebo in Men With Metastatic Castratio
 n-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agen
 ts\n\nPrimary completion date: 2027-09-30 (estimated)\nOriginally planned:
  2028-01-14 (-3.5 months)\nPhase 3 · Oncology · Metastatic Castration-Se
 nsitive Prostate Cancer\nEnrollment: 1898 · Sites: 322\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct
 =NCT06120491\nhttps://clinicaltrials.gov/study/NCT06120491
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06120491
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Datopotamab deruxtecan (Dato-DXd) readout (P2) · AstraZeneca $AZN
DESCRIPTION:Study of Dato-DXd as Monotherapy and in Combination With Anti-c
 ancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\
 n\nPrimary completion date: 2027-10-01 (estimated)\nOriginally planned: 20
 25-06-02 (+28.0 months)\nPhase 2 · Oncology · Endometrial Cancer\, Gastr
 ic Cancer\, Metastatic Castration-resistant Prostate Cancer\nEnrollment: 4
 54 · Sites: 96\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT05489211\nhttps://clinicaltrials.gov
 /study/NCT05489211
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05489211
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:OSTARA readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate Safety and Efficacy of Osimertinib and A
 mivantamab in Participants With Non-small Cell Lung Cancer With Common Epi
 dermal Growth Factor Receptor Mutations\n\nPrimary completion date: 2027-1
 0-01 (estimated)\nPhase 2 · Oncology · Non-Small Cell Lung Cancer (NSCLC
 )\nEnrollment: 60 · Sites: 28\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05801029\nhttps://cli
 nicaltrials.gov/study/NCT05801029
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05801029
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471257-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:BAIYUN readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate Efficacy and Safety of PT027 Compared Wi
 th PT007 in Symptomatic Chinese Adults With Asthma\n\nPrimary completion d
 ate: 2027-10-04 (estimated)\nOriginally planned: 2026-10-30 (+11.1 months)
 \nPhase 3 · Respiratory · Asthma\nEnrollment: 1000 · Sites: 102\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/rad
 ar.html?nct=NCT06471257\nhttps://clinicaltrials.gov/study/NCT06471257
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06471257
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824987-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:APPRECIATE readout (P2) · AstraZeneca $AZN
DESCRIPTION:Dose-Ranging Safety\, Tolerability\, and Efficacy Study of AZD2
 373 in Participants With APOL1-Mediated Kidney Disease\n\nPrimary completi
 on date: 2027-10-04 (estimated)\nPhase 2 · Cardio-Met · APOL1-Mediated K
 idney Disease\nEnrollment: 63 · Sites: 96\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06824987\
 nhttps://clinicaltrials.gov/study/NCT06824987
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06824987
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744647-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:CONCORD readout (P2) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Re
 jection After Kidney Transplantation\n\nPrimary completion date: 2027-10-1
 1 (estimated)\nOriginally planned: 2027-04-05 (+6.2 months)\nPhase 2 · GI
 ·Renal·Heme · Antibody-Mediated Rejection\, Kidney Transplantation\, Bi
 opsy-proven Histologic Scores\nEnrollment: 47 · Sites: 51\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?
 nct=NCT06744647\nhttps://clinicaltrials.gov/study/NCT06744647
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06744647
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160608-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Tarperprumig readout (P2) · Alexion Pharmaceuticals\, Inc. $AZN
DESCRIPTION:Safety and Efficacy of Tarperprumig in Adult Participants With 
 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis\n\nPrima
 ry completion date: 2027-10-11 (estimated)\nPhase 2 · Immuno · Anti-Neut
 rophil Cytoplasmic Antibody-Associated Vasculitis\nEnrollment: 78 · Sites
 : 57\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT07160608\nhttps://clinicaltrials.gov/study/NCT0
 7160608
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07160608
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Laroprovstat readout (P3) · AstraZeneca $AZN
DESCRIPTION:A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosu
 vastatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C 
 in LLT-naïve Patients\n\nPrimary completion date: 2027-10-11 (estimated)\
 nPhase 3 · Cardio-Met · Hypercholesterolemia\nEnrollment: 204 · Sites: 
 42\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netli
 fy.app/radar.html?nct=NCT07930507\nhttps://clinicaltrials.gov/study/NCT079
 30507
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07930507
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307665-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:ACADIA readout (P3) · AstraZeneca $AZN
DESCRIPTION:Evaluating the Efficacy and Safety of PT027 Compared With PT007
  Administered As Needed in Participants 12 to < 18 Years of Age With Asthm
 a\n\nPrimary completion date: 2027-10-13 (estimated)\nPhase 3 · Respirato
 ry · Asthma\nEnrollment: 440 · Sites: 157\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06307665
 \nhttps://clinicaltrials.gov/study/NCT06307665
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06307665
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044336-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Puxitatug Samrotecan readout (P3) · AstraZeneca $AZN
DESCRIPTION:Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B
 7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)\n\nPrimary compl
 etion date: 2027-10-15 (estimated)\nPhase 3 · Oncology · Endometrial Can
 cer\, Malignant Solid Tumour\nEnrollment: 800 · Sites: 320\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html
 ?nct=NCT07044336\nhttps://clinicaltrials.gov/study/NCT07044336
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07044336
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:CAPItello-292 readout (P3) · AstraZeneca $AZN
DESCRIPTION:Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR
 +/HER2- Breast Cancer (CAPItello-292)\n\nPrimary completion date: 2027-11-
 01 (estimated)\nOriginally planned: 2024-10-21 (+36.3 months)\nPhase 3 · 
 Oncology · Locally Advanced (Inoperable) or Metastatic Breast Cancer\nEnr
 ollment: 893 · Sites: 225\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://trialsonar.netlify.app/radar.html?nct=NCT04862663\nhttps://clinica
 ltrials.gov/study/NCT04862663
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04862663
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:AVANZAR readout (P3) · AstraZeneca $AZN
DESCRIPTION:Phase III\, Open-label\, First-line Study of Dato-DXd in Combin
 ation With Durvalumab and Carboplatin for Advanced NSCLC Without Actionabl
 e Genomic Alterations\n\nPrimary completion date: 2027-11-01 (estimated)\n
 Originally planned: 2027-05-20 (+5.4 months)\nPhase 3 · Oncology · NSCLC
 \nEnrollment: 1350 · Sites: 254\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05687266\nhttps://c
 linicaltrials.gov/study/NCT05687266
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05687266
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624450-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:TILIA readout (P3) · AstraZeneca $AZN
DESCRIPTION:Efficacy and Safety of Tozorakimab in Patients Hospitalised for
  Viral Lung Infection Requiring Supplemental Oxygen\n\nPrimary completion 
 date: 2027-11-04 (estimated)\nOriginally planned: 2024-05-09 (+41.9 months
 )\nPhase 3 · Infectious · Viral Lung Infection and Acute Respiratory Fai
 lure\nEnrollment: 3527 · Sites: 473\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05624450\nhttps
 ://clinicaltrials.gov/study/NCT05624450
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05624450
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Sonesitatug Vedotin readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study of Novel Agents or Combinations as Perioperative Treatm
 ent in Participants With Locally Advanced Resectable Gastroesophageal Aden
 ocarcinoma\n\nPrimary completion date: 2027-11-09 (estimated)\nOriginally 
 planned: 2026-12-18 (+10.7 months)\nPhase 2 · Oncology · Gastroesophagea
 l Adenocarcinoma\nEnrollment: 100 · Sites: 70\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07069
 712\nhttps://clinicaltrials.gov/study/NCT07069712
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07069712
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276581-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:LaunchPAD-RA readout (P2) · AstraZeneca $AZN
DESCRIPTION:A Study to Investigate Efficacy and Safety of AZD1163 in Partic
 ipants With Rheumatoid Arthritis\n\nPrimary completion date: 2027-11-12 (e
 stimated)\nPhase 2 · Immuno · Rheumatoid Arthritis\nEnrollment: 320 · S
 ites: 147\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT07276581\nhttps://clinicaltrials.gov/study
 /NCT07276581
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07276581
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
